Drug intelligence / Profile preview

ASD001

Development stage: Preclinical
Lead developer: Ascendo Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intranasal, Injectable, Oral, Topical

Overview

ASD001 is a preclinical-stage monoclonal antibody being developed by Ascendo Biotechnology for the treatment of autoimmune diseases, including systemic lupus erythematosus (SLE) and inflammatory bowel disease (IBD). It targets the CD11b receptor (Integrin alpha M) on myeloid cells. Unlike many therapies that inhibit immune targets, ASD001 acts as an activating antibody that modulates the innate immune system to reprogram overactive immune cells, thereby restoring immune homeostasis and reducing chronic inflammation. Preclinical mouse models have demonstrated its potential in suppressing overactive immune responses in IBD, and the company plans to file a U.S. Investigational New Drug (IND) application in 2026.

Targets

αMβ2 (Integrin αMβ2)

Beyond the preview

Go deeper on ASD001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASD001.

Explore the full profile